Publications

5813 Results

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: Vaginal Cancers

Authors
Y Chae;J Czeskleba;S Patel;A Menter;W Robinson;N Jones;M Rampurwala;A Naing;J Beck;C Moloney;L Chung;C McLeod;H Chen;E Sharon;S Threlkel;M Othus;C Ryan;C Blanke;R Kurzrock
Journal / Conference
AACR 2025 Meeting, poster; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT092
Year
2025
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S1609

Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial

Authors
K Kendra;S Bellasea;Z Eroglu;S Hu-Lieskovan;K Campbell;W Carson;D Wada;J Plaza;J Sosman;G In;A Ikeguchi;J Hyngstrom;A Brohl;N Khushalani;J Markowitz;G Negrea;S Kasbari;G Doolittle;U Swami;T Roberts;E Medina;I Baselga Carretero;C Gonzalez;I Perez Garcilazo;A Vega-Crespo;J Ming Chen;N Naser Al Deen;S Patel;E Sharon;J Moon;M Wu;A Ribas
Journal / Conference
Nature Medicine. 2025 Nov;31(11):3668-3674. doi: 10.1038/s41591-025-03875-5. Epub 2025 Aug 14.
Year
2025
Research Committee(s)
Melanoma
PMID
PMID40813711
PMC
PMC12419231
Study Number(s)
S1512

A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT# 04511013)

Authors
Z Eroglu;J Moon;Y Najjar;R Kotecha;M Wu;V Spektor;N Khushalani;L Korde;E Sharon;K Grossmann;J Kirkwood;J Wolchok;S Patel;H Tawbi
Journal / Conference
ASCO Annual Meeting (May 30-June 3, 2025, Chicago, IL), oral, Abstract # LBA9507
Year
2025
Research Committee(s)
Melanoma
Study Number(s)
S2000

(S1900E: A Phase II Study of AMG 510 in Patients With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-Map Sub-Study))

Authors
S Padda;M Redman;D Gerber;K Minichiello;D Mehta;S Mashru;H Hakim;J Brahmer;J Bradley;T Stinchcombe;J Gray;K Kelly;D Kozono;M Edelman;K Reckamp;H Borghaei;R Herbst;S Ramalingam;J Neal
Journal / Conference
ASCO Annual Meeitng (May 30-June 3, 2025, Chicago), rapid oral, Abstract # 8518
Year
2025
Research Committee(s)
Lung
Study Number(s)
S1900E

Androgen pathway gene expression and response to hormonal therapy in prostate cancer (SWOG S1216)

Authors
J Pinski;S Ingles;Z Minojlovic;S Xiong;D Weisenberger;A Goldkorn;C Tangen;D McConkey;P Lara;M Hussain;D Quinn;I Thompson;S Lerner;T Dorff;N Agarwal
Journal / Conference
ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), publication only, Abstract # e17109
Year
2025
Research Committee(s)
Genitourinary
Study Number(s)
S1216

Prognostic Value of Circulating Tumor DNA in Advanced Stage Classic Hodgkin Lymphoma Patients Treated on SWOG S1826

Authors
J Paczkowska;M Kaczkowiak;M LeBlanc;C Stewart;A Herrera;J Fernando del Castillo;S Castellino;S Rutherford;A Evens;K Davison;H Li;D Neuberg;M Murakami;J Makker;B Kahl;J Leonard;N Bartlett;S Smith;J Song;K Kelly;G Getz;JW Friedberg;M Shipp
Journal / Conference
ICML 2025 Meeting (Lugano, Switzerland, from 17 to 21 June 2025)
Year
2025
Research Committee(s)
Lymphoma
Study Number(s)
S1826

Baseline autoimmune diseases and characteristics of solid tumor patients on immune checkpoint inhibitor (ICI) therapy enrolled in a prospective study of immune-related adverse events (irAEs): SWOG S2013 (I-CHECKIT)

Authors
K Gunturu;J Unger;D Hershman;A Darke;N Kuderer;S Hu-Lieskovan;J Nabi;M Sochat;NL Henry;M Fisch
Journal / Conference
ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), poster, Abstract # 2600 Poster Bd # 247
Year
2025
Research Committee(s)
Symptom Management and Survivorship
Study Number(s)
S2013

Efficacy and Toxicity of Nivolumab and Ipilimumab in Rare Cancer Brain Metastases: A Multi-Center Basket Trial Analysis (NCI/SWOG S1609)

Authors
M Ahluwalia;S Solomon;S Patel;S Sarfraz;M Othus;Y Chae;R Kurzrock
Journal / Conference
ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), poster; Abstract # 2619 Poster Bd # 266
Year
2025
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S1609

Combined genomic profiling of cell-free DNA (cfDNA) and circulating tumor cell DNA (ctcDNA) in S1802, a prospective phase 3 trial for metastatic prostate cancer (mHSPC)

Authors
D Bsteh;J Buckley;S Mitchell;D Ostrow;J Parmentier;S Jahan;S Sadis;J Smith;J Ni;X Peng;D McConkey;T Dorff;S Lerner;A Aparicio;B Chapin;V Duddalwar;T Triche;A Goldkorn
Journal / Conference
ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), publication only, Abstract # e17111
Year
2025
Research Committee(s)
Genitourinary
Study Number(s)
S1802

SWOG S2302, PRAGMATICA-LUNG: A Pragmatic Trial Designed to Increase Participant Representation

Authors
K Reckamp;M Redman;K Dragnev;M Khalil;B Henick;J Moon;P Ahmadzai;M LeBlanc;D Carrizosa;R Herbst;C Blanke;J Gray
Journal / Conference
ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), rapid oral, Abstract # 11016
Year
2025
Research Committee(s)
Lung
Study Number(s)
S2302